149 related articles for article (PubMed ID: 24602376)
1. Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices.
Curto S; Ghislandi S; van de Vooren K; Duranti S; Garattini L
Health Policy; 2014 Jun; 116(2-3):182-7. PubMed ID: 24602376
[TBL] [Abstract][Full Text] [Related]
2. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis.
Bocquet F; Paubel P; Fusier I; Cordonnier AL; Le Pen C; Sinègre M
Appl Health Econ Health Policy; 2014 Jun; 12(3):315-26. PubMed ID: 24578185
[TBL] [Abstract][Full Text] [Related]
4. [Can we transfer the mechanisms of the generics market to biosimilars?].
Jacke CO; Wild F
Versicherungsmedizin; 2016 Dec; 68(4):168-72. PubMed ID: 29144113
[TBL] [Abstract][Full Text] [Related]
5. [Experiences with price competition of biosimilar drugs in Hungary].
Hornyák L; Nagy Z; Tálos Z; Endrei D; Ágoston I; Csákvári T; Boncz I
Acta Pharm Hung; 2014; 84(2):83-7. PubMed ID: 25167704
[TBL] [Abstract][Full Text] [Related]
6. Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.
Barbier L; Simoens S; Soontjens C; Claus B; Vulto AG; Huys I
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073861
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.
Bocquet F; Paubel P; Fusier I; Cordonnier AL; Sinègre M; Le Pen C
Appl Health Econ Health Policy; 2015 Feb; 13(1):47-59. PubMed ID: 25189295
[TBL] [Abstract][Full Text] [Related]
8. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
[TBL] [Abstract][Full Text] [Related]
9. A Cross-National Comparison of Biosimilars Pricing in Argentina, Australia, Brazil, and Italy.
da Silva Machado FL; Cañás M; Urtasun MA; Marín GH; Albuquerque FC; Pont L; Convertino I; Bonaso M; Tuccori M; Kirchmayer U; Lopes LC
Ther Innov Regul Sci; 2024 May; 58(3):549-556. PubMed ID: 38436905
[TBL] [Abstract][Full Text] [Related]
10. Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary.
Hornyák L; Nagy Z; Ilku L; Tálos Z; Endrei D; Ágoston I; Csákvári T; Danku N; Répásy B; Boncz I
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):725-731. PubMed ID: 30763134
[No Abstract] [Full Text] [Related]
11. Competitive tenders on analogue hospital pharmaceuticals in Denmark 2017-2020.
Ehlers LH; Jensen MB; Schack H
J Pharm Policy Pract; 2022 Oct; 15(1):69. PubMed ID: 36273196
[TBL] [Abstract][Full Text] [Related]
12. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
Aapro M; Cornes P; Abraham I
J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
[TBL] [Abstract][Full Text] [Related]
13. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
14. Bullying biosimilars: cheaper drugs stymied in USA.
The Lancet Gastroenterology Hepatology
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669
[No Abstract] [Full Text] [Related]
15. The economic implications of biosimilars.
Singh SC; Bagnato KM
Am J Manag Care; 2015 Dec; 21(16 Suppl):s331-40. PubMed ID: 26788809
[TBL] [Abstract][Full Text] [Related]
16. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.
Grewal S; Ramsey S; Balu S; Carlson JJ
Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):447-454. PubMed ID: 29757040
[TBL] [Abstract][Full Text] [Related]
17. Effect of generic drug competition on the price of prescription drugs in Ontario.
Lexchin J
CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of biosimilar epoetins in nephrology in the United States.
Fishbane S; Shah HH
Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
[TBL] [Abstract][Full Text] [Related]
19. Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly.
Stajszczyk M; Batko K; Żuber ZM; Kwiatkowska B; Krajewska-Włodarczyk M; Batko B
BioDrugs; 2024 Jun; ():. PubMed ID: 38861154
[TBL] [Abstract][Full Text] [Related]
20. First biosimilar drug set to enter US market.
Ledford H
Nature; 2015 Jan; 517(7534):253-4. PubMed ID: 25592512
[No Abstract] [Full Text] [Related]
[Next] [New Search]
